Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Playing to Advance Care: A Championship Mindset in Clinical Research
Beyond the Endpoint
34 minutes 35 seconds
5 months ago
Playing to Advance Care: A Championship Mindset in Clinical Research
What do championship sports teams and successful research institutions have in common?
In the season finale of Beyond the Endpoint, Dr. Adrian Hernandez joins hosts Manesh Patel and Emily O’Brien to break down what clinical research institutions can learn from their counterparts on the court. From basketball dynasties to resilient mindsets, Dr. Hernandez offers a powerful playbook on building strong research systems, prioritizing patients, and why sharing “negative” results matters.
Don’t miss the wrap-up to Season 1!
🔗 Access resources related to this episode https://dcri.org/blog/ep-10-playing-advance-care-championship-mindset-clinical-research
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.